Truist analyst Robyn Karnauskas initiated coverage of Coherus Biosciences (CHRS) with a Buy rating and $24 price target. Truist is positive on this growing biosimilar franchise with a track record of taking share in competitive markets such as Amgen’s (AMGN) Neulasta, the analyst tells investors in a research note. The firm further cites the expected 2023 approval of underappreciated IO asset Toripalimal providing upside potential while noting the company’s management offering excellent commercial experience with "top-notch record" and a history of execution.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CHRS:
- Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
- Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- FDA resuming China lab inspections could benefit Amicus, BeiGene, Barron’s says
- Coherus Biosciences management to meet with Truist
- Coherus Biosciences upgraded to Buy from Neutral at UBS
